Due to an error in PharMEDium’s electronic customer ordering system, 45 lots of Hydromorphone HCl in 0.9% Sodium Chloride 1mL in 3mL BD Syringe (NDC # 61553-352-78) have been recalled as the product contains sulfite, although the system indicated it was sulfite-free.
While no adverse events have been reported to date, the use of this product could potentially cause serious adverse reactions (ie, severe bronchospasm, anaphylaxis) in patients with a sulfite allergy. A total of 28,140 syringes have been distributed to 6 customers, all of which have been contacted.
Hydromorphone Injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate.
For more information visit pharmedium.com.
This article originally appeared on MPR